98%
921
2 minutes
20
Nurr1, a transcription factor belonging to the orphan nuclear receptor, has an essential role in the generation and maintenance of dopaminergic neurons and is important in the pathogenesis of Parkinson' disease (PD). In addition, Nurr1 has a non-neuronal function, and it is especially well known that Nurr1 has an anti-inflammatory function in the Parkinson's disease model. However, the molecular mechanisms of Nurr1 have not been elucidated. In this study, we describe a novel mechanism of Nurr1 function. To provide new insights into the molecular mechanisms of Nurr1 in the inflammatory response, we performed Chromatin immunoprecipitation sequencing (ChIP-Seq) on LPS-induced inflammation in BV2 cells and finally identified the RasGRP1 gene as a novel target of Nurr1. Here, we show that Nurr1 directly binds to the RasGRP1 intron to regulate its expression. Moreover, we also identified that RasGRP1 regulates the Ras-Raf-MEK-ERK signaling cascade in LPS-induced inflammation signaling. Finally, we conclude that RasGRP1 is a novel regulator of Nurr1's mediated inflammation signaling.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329810 | PMC |
http://dx.doi.org/10.1038/s41598-020-67549-7 | DOI Listing |
Neurosci Bull
September 2025
Laboratory Animal Center, Fudan University, Shanghai, 200032, China.
Nr4a2 (Nurr1) is well known to be vital for midbrain dopaminergic neurons. Recent single-cell RNA analyses reveal that Nr4a2 is expressed in lateral cerebral regions, within neurons named L4/L5/L6 IT Car3. These neurons have attracted intense attention for the molecular mechanisms underlying their development and functions.
View Article and Find Full Text PDFACS Omega
September 2025
Key Laboratory of Liaoning Province for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital, Dalian Medical University, 116021 Dalian, China.
Former studies indicate that nuclear receptor subfamily 4 group A member 2 (Nurr1, NR4A2), a transcription factor, is regarded as a potential therapeutic target for central nervous system diseases, and many studies have focused on the development and optimization of agonists of Nurr1. Recent studies have shown that Nurr1 is upregulated in many other diseases. However, there is still a lack of effective inverse Nurr1 agonists as a therapeutic strategy or as pharmacological tools to counteract the receptor's inherent activity.
View Article and Find Full Text PDFPharmacol Rep
August 2025
Department of Oriental Pharmaceutical Science and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.
Background: Parkinson's disease (PD) is characterized by progressive dopaminergic neuronal loss, and current treatments are limited by their inability to prevent neurodegeneration. NURR1, a crucial transcription factor for dopaminergic neuron survival, has emerged as a promising therapeutic target. This study investigated whether Saikosaponin A (SSA), a bioactive compound from Bupleuri radix, exhibits neuroprotective effects through NURR1-mediated mechanisms in 6-hydroxydopamine (6-OHDA)-induced PD models.
View Article and Find Full Text PDFNeurogenetics
August 2025
Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, 630 003, India.
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder which seriously affects human health. Worldwide, there has been a significant increase in the incidence rate of PD reported in many populations. Several epigenetic factors are associated with pathogenesis of the PD.
View Article and Find Full Text PDFJ Med Chem
August 2025
Department of Pharmacy, Ludwig-Maximilians-Universität München, 81377 Munich, Germany.
Nuclear receptor related 1 (Nurr1) is a neuronal ligand-activated transcription factor implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and multiple sclerosis, which has fueled the development of Nurr1 modulators. Among them, the clinically studied dihydroorotate dehydrogenase (DHODH) inhibitor vidofludimus was found to exhibit strong Nurr1 agonism. Here, we aimed to establish a vidofludimus-derived Nurr1 agonist lacking DHODH inhibitor potency as a tool.
View Article and Find Full Text PDF